Search
Ethanolamine
go.drugbank.com/drugs/DB03994InvestigationalA viscous, hygroscopic amino alcohol with an ammoniacal odor. It is widely distributed in biological tissue and is a component of lecithin. … It is used as a surfactant, fluorimetric reagent, and to remove CO2 and H2S from natural gas and other gases.
Pamiparib
go.drugbank.com/drugs/DB14769InvestigationalPamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression … on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).
Radotinib
go.drugbank.com/drugs/DB12323InvestigationalRadotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10774ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10775ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10780ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10781ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10782ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10792ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Bolivia/559/2013 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB11034ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.